- WuXi Biologics released its “Green CRDMO White Paper” during its first CRDMO+ Open Day, outlining end-to-end sustainable solutions for biologics.
- The paper details 242 energy-saving cases and highlights measurable environmental achievements, including reductions in carbon emissions, water consumption, and waste generation.
WuXi Biologics has published its “Green CRDMO White Paper” at the company’s first CRDMO+ Open Day. The white paper presents the company’s approach to sustainability across contract research, development, and manufacturing activities, and its efforts to drive a greener global biologics supply chain.
The paper outlines WuXi Biologics’ innovation in green technologies applied throughout research, development, and manufacturing of biologics. A total of 242 energy-saving cases are included, covering five energy-saving scenarios, 12 energy systems, and 25 technology categories. The company reported that in 2024 more than 90% of its Kaizen projects delivered ESG benefits, such as reduced carbon emissions, water use, and waste.
The launch follows the recognition of WuXi Biologics’ Green CRDMO model in the “20 Case Examples for 20 Years” report by the United Nations Global Compact. It was the only pharmaceutical case included in the report.
WuXi Biologics said it has adopted an integrated strategy with measurable targets for addressing climate change, recently strengthened with Science Based Targets initiative (SBTi) approval of its new target matrix. Dr Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, stated: “We are pleased to release the Green CRDMO White Paper with the aspiration that our insights and best practices will inspire and empower the whole industry to drive sustainable progress.”
The company has received multiple ESG recognitions, including an MSCI AAA rating, an EcoVadis Platinum Medal, listings in the Dow Jones Sustainability Indices and FTSE4Good Index Series, and leadership-level scores from CDP in water security and climate change.
